Eight Sleep raises US$100m for AI sleep tech and medical expansion
Eight Sleep, a New York sleep technology company, raised US$100.0m ($152.8m) to accelerate its AI roadmap, expand into medical applications and grow internationally. Investors included HSG (HongShan), Valor Equity Partners, Atreides, Founders Fund and Y Combinator, with individual participation from Charles Leclerc and Zak Brown.
Transaction snapshot
Deal value: US$100.0m ($152.8m) at today’s USD/AUD mid-market rate.
Deal multiples: N/A
Deal type: Series D
Investors: HSG (HongShan), Valor Equity Partners, Atreides, Founders Fund, Y Combinator; individuals Charles Leclerc and Zak Brown.
The round will fund an AI “Sleep Agent,” build condition-specific interventions and support entry into regulated medical use cases, including work toward FDA filings for menopausal sleep and sleep apnoea. International expansion includes a push into China.
Eight Sleep says it has surpassed US$500m ($763.9m) in Pod sales and grown revenue 10x since launching the product, with over 1 billion hours of sleep data analysed. It ships to more than 30 countries, including Australia.
The company’s valuation has roughly doubled since its 2021 Series C, when it was about US$500m ($763.9m). Recent reporting places the new valuation near US$1.0b ($1.5b). Total funding now exceeds roughly US$260m ($397.2m).
Eight Sleep plans to use the fresh capital to advance AI-driven temperature, elevation and routine adjustments, moving from passive tracking to proactive optimisation in the sleep environment. The business is also targeting retail expansion and broader consumer adoption beyond early tech adopters.
